表紙：融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

市場調査レポート

商品コード

1208546

融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Fusion Inhibitors Market (Indication: HIV/AIDS and COVID-19; and Route of Administration: Parenteral and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

出版日: 2022年12月08日 | 発行: Transparency Market Research

| ページ情報: 英文 185 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 898,978円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,364,368円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,829,758円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.13円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の融合阻害剤市場について調査し、市場の概要とともに、2022年～2031年の予測、投与経路別、適応症別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

市場参入企業-競合マトリクス
市場シェア/ランキング分析、企業別、2021年
企業プロファイル
- Bristol-Myers Squibb Company
- PeptidePharma
- Incyte
- Astrazeneca
- ViiV Healthcare Limited
- Frontier Bio Corporation
- Trimeris, Inc.
- Progenics Pharmaceuticals
- Schering-Plough（Merck &Co.）
- Biogen
- Vanderbilt University
- Genentech

図表

List of Tables

Table 01: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 02: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by 2017-2031, by Indication
Table 03: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 07: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 08: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 11: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 12: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 15: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 16: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 19: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 23: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 24: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Fusion Inhibitors Market Value Share, by Route of Administration, 2021
Figure 03: Global Fusion Inhibitors Market Value Share, by Indication, 2021
Figure 04: Global Fusion Inhibitors Market Value Share, by Distribution Channel, 2021
Figure 05: Global Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 06: Global Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 09: Global Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
Figure 10: Global Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
Figure 11: Global Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 12: Global Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 13: Global Fusion Inhibitors Market Value Share Analysis, by Region, 2021 and 2031
Figure 14: Global Fusion Inhibitors Market Attractiveness Analysis, by Region, 2022-2031
Figure 15: North America Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
Figure 16: North America Fusion Inhibitors Market Value Share Analysis, by Country, 2021 and 2031
Figure 17: North America Fusion Inhibitors Market Attractiveness Analysis, by Country, 2022-2031
Figure 18: North America Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 19: North America Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 20: North America Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
Figure 21: North America Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
Figure 22: North America Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 23: North America Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 24: Europe Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
Figure 25: Europe Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 26: Europe Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 27: Europe Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 28: Europe Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 29: Europe Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
Figure 30: Europe Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
Figure 31: Europe Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 32: Europe Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 33: Asia Pacific Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
Figure 34: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 35: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 36: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 37: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 38: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
Figure 39: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
Figure 40: Asia Pacific Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Asia Pacific Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 42: Latin America Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
Figure 43: Latin America Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 44: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 45: Latin America Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 46: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 47: Latin America Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
Figure 48: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
Figure 49: Latin America Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 50: Latin America Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 51: Middle East & Africa Fusion Inhibitors Market Value (US$ Mn) Forecast, 2017-2031
Figure 52: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 53: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 54: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 55: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 56: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Indication, 2021 and 2031
Figure 57: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Indication, 2022-2031
Figure 58: Middle East & Africa Fusion Inhibitors Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 59: Middle East & Africa Fusion Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 60: Company Share Analysis, 2021

Product Code: TMRGL85266

The report provides revenue of the global fusion inhibitors market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fusion inhibitors market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fusion inhibitors market.

The report delves into the competitive landscape of the global fusion inhibitors market. Key players operating in the global fusion inhibitors market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global fusion inhibitors market profiled in this report.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fusion Inhibitors Market

4. Market Overview

4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Fusion Inhibitors Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Key Mergers & Acquisitions
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. Drug Pricing Analysis
5.4. Pipeline Analysis
5.5. Covid-19 Pandemic Impact on the Industry

6. Global Fusion Inhibitors Market Analysis and Forecast, by Route of Administration

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Route of Administration, 2017-2031
- 6.3.1. Oral
- 6.3.2. Parenteral
6.4. Market Attractiveness Analysis, by Route of Administration

7. Global Fusion Inhibitors Market Analysis and Forecast, by Indication

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
- 7.3.1. HIV/AIDS
- 7.3.2. COVID-19
7.4. Market Attractiveness Analysis, by Indication

8. Global Fusion Inhibitors Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Retail Pharmacies
- 8.3.2. Online Pharmacies
- 8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Fusion Inhibitors Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Fusion Inhibitors Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Route of Administration, 2017-2031
- 10.2.1. Oral
- 10.2.2. Parenteral
10.3. Market Value Forecast, by Indication, 2017-2031
- 10.3.1. HIV/AIDS
- 10.3.2. COVID-19
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.4.1. Retail Pharmacies
- 10.4.2. Online Pharmacies
- 10.4.3. Others
10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Route of Administration
- 10.6.2. By Indication
- 10.6.3. By Distribution Channel
- 10.6.4. By Country

11. Europe Fusion Inhibitors Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Route of Administration, 2017-2031
- 11.2.1. Oral
- 11.2.2. Parenteral
11.3. Market Value Forecast, by Indication, 2017-2031
- 11.3.1. HIV/AIDS
- 11.3.2. COVID-19
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.4.1. Retail Pharmacies
- 11.4.2. Online Pharmacies
- 11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Route of Administration
- 11.6.2. By Indication
- 11.6.3. By Distribution Channel
- 11.6.4. By Country/Sub-region

12. Asia Pacific Fusion Inhibitors Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Route of Administration, 2017-2031
- 12.2.1. Oral
- 12.2.2. Parenteral
12.3. Market Value Forecast, by Indication, 2017-2031
- 12.3.1. HIV/AIDS
- 12.3.2. COVID-19
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.4.1. Retail Pharmacies
- 12.4.2. Online Pharmacies
- 12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Route of Administration
- 12.6.2. By Indication
- 12.6.3. By Distribution Channel
- 12.6.4. By Country/Sub-region

13. Latin America Fusion Inhibitors Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Route of Administration, 2017-2031
- 13.2.1. Oral
- 13.2.2. Parenteral
13.3. Market Value Forecast, by Indication, 2017-2031
- 13.3.1. HIV/AIDS
- 13.3.2. COVID-19
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.4.1. Retail Pharmacies
- 13.4.2. Online Pharmacies
- 13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Route of Administration
- 13.6.2. By Indication
- 13.6.3. By Distribution Channel
- 13.6.4. By Country/Sub-region

14. Middle East & Africa Fusion Inhibitors Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Route of Administration, 2017-2031
- 14.2.1. Oral
- 14.2.2. Parenteral
14.3. Market Value Forecast, by Indication, 2017-2031
- 14.3.1. HIV/AIDS
- 14.3.2. COVID-19
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.4.1. Retail Pharmacies
- 14.4.2. Online Pharmacies
- 14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Route of Administration
- 14.6.2. By Indication
- 14.6.3. By Distribution Channel
- 14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share/Ranking Analysis, by Company, 2021
15.3. Company Profiles
- 15.3.1. Bristol-Myers Squibb Company
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Strategic Overview
- 15.3.2. PeptidePharma
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Strategic Overview
- 15.3.3. Incyte
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Strategic Overview
- 15.3.4. Astrazeneca
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Strategic Overview
- 15.3.5. ViiV Healthcare Limited
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Strategic Overview
- 15.3.6. Frontier Bio Corporation
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Strategic Overview
- 15.3.7. Trimeris, Inc.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Strategic Overview
- 15.3.8. Progenics Pharmaceuticals
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Strategic Overview
- 15.3.9. Schering-Plough (Merck & Co.)
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Strategic Overview
- 15.3.10. Biogen
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. SWOT Analysis
  - 15.3.10.4. Strategic Overview
- 15.3.11. Vanderbilt University
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Product Portfolio
  - 15.3.11.3. SWOT Analysis
  - 15.3.11.4. Strategic Overview
- 15.3.12. Genentech
  - 15.3.12.1. Company Overview
  - 15.3.12.2. Product Portfolio
  - 15.3.12.3. SWOT Analysis
  - 15.3.12.4. Strategic Overview

融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Fusion Inhibitors Market (Indication: HIV/AIDS and COVID-19; and Route of Administration: Parenteral and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

目次

第1章序文

第2章前提と調査手法

第3章エグゼクティブサマリー：世界の融合阻害剤市場

第4章市場概要

第5章主な洞察

第6章世界の融合阻害剤市場の分析と予測、投与経路別

第7章世界の融合阻害剤市場の分析と予測、適応症別

第8章世界の融合阻害剤市場の分析と予測、流通チャネル別

第9章世界の融合阻害剤市場の分析と予測、地域別

第10章北米の融合阻害剤市場の分析と予測

第11章欧州の融合阻害剤市場の分析と予測

第12章アジア太平洋の融合阻害剤市場の分析と予測

第13章ラテンアメリカの融合阻害剤市場の分析と予測

第14章中東・アフリカの融合阻害剤市場の分析と予測

第15章競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Fusion Inhibitors Market

4. Market Overview

5. Key Insights

6. Global Fusion Inhibitors Market Analysis and Forecast, by Route of Administration

7. Global Fusion Inhibitors Market Analysis and Forecast, by Indication

8. Global Fusion Inhibitors Market Analysis and Forecast, by Distribution Channel

9. Global Fusion Inhibitors Market Analysis and Forecast, by Region

10. North America Fusion Inhibitors Market Analysis and Forecast

11. Europe Fusion Inhibitors Market Analysis and Forecast

12. Asia Pacific Fusion Inhibitors Market Analysis and Forecast

13. Latin America Fusion Inhibitors Market Analysis and Forecast

14. Middle East & Africa Fusion Inhibitors Market Analysis and Forecast

15. Competition Landscape

融合阻害剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Fusion Inhibitors Market (Indication: HIV/AIDS and COVID-19; and Route of Administration: Parenteral and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の融合阻害剤市場

第4章 市場概要

第5章 主な洞察

第6章 世界の融合阻害剤市場の分析と予測、投与経路別

第7章 世界の融合阻害剤市場の分析と予測、適応症別

第8章 世界の融合阻害剤市場の分析と予測、流通チャネル別

第9章 世界の融合阻害剤市場の分析と予測、地域別

第10章 北米の融合阻害剤市場の分析と予測

第11章 欧州の融合阻害剤市場の分析と予測

第12章 アジア太平洋の融合阻害剤市場の分析と予測

第13章 ラテンアメリカの融合阻害剤市場の分析と予測

第14章 中東・アフリカの融合阻害剤市場の分析と予測

第15章 競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Fusion Inhibitors Market

4. Market Overview

5. Key Insights

6. Global Fusion Inhibitors Market Analysis and Forecast, by Route of Administration

7. Global Fusion Inhibitors Market Analysis and Forecast, by Indication

8. Global Fusion Inhibitors Market Analysis and Forecast, by Distribution Channel

9. Global Fusion Inhibitors Market Analysis and Forecast, by Region

10. North America Fusion Inhibitors Market Analysis and Forecast

11. Europe Fusion Inhibitors Market Analysis and Forecast

12. Asia Pacific Fusion Inhibitors Market Analysis and Forecast

13. Latin America Fusion Inhibitors Market Analysis and Forecast

14. Middle East & Africa Fusion Inhibitors Market Analysis and Forecast

15. Competition Landscape

第1章序文

第2章前提と調査手法

第3章エグゼクティブサマリー：世界の融合阻害剤市場

第4章市場概要

第5章主な洞察

第6章世界の融合阻害剤市場の分析と予測、投与経路別

第7章世界の融合阻害剤市場の分析と予測、適応症別

第8章世界の融合阻害剤市場の分析と予測、流通チャネル別

第9章世界の融合阻害剤市場の分析と予測、地域別

第10章北米の融合阻害剤市場の分析と予測

第11章欧州の融合阻害剤市場の分析と予測

第12章アジア太平洋の融合阻害剤市場の分析と予測

第13章ラテンアメリカの融合阻害剤市場の分析と予測

第14章中東・アフリカの融合阻害剤市場の分析と予測

第15章競合情勢